Hormonal
Duodenal mucosal ablation (DMR) significantly reduces HbA1c in patients with Type 2 Diabetes, particularly those with high fasting glucose or insulin-requiring disease, by targeting the proximal small bowel to mimic the metabolic effects of bariatric surgery.
If you have Type 2 Diabetes and struggle to control your blood sugar with diet and medication, especially if you require insulin or have high fasting glucose, ask your doctor about Duodenal Mucosal Resurfacing (DMR). This is a minimally invasive endoscopic procedure that ablates a small section of your small intestine to improve how your body handles glucose. It is not a weight-loss surgery, but it can significantly lower your HbA1c and potentially reduce or eliminate your need for insulin. While it is a one-time procedure, it carries risks like stricture formation, so it is best considered for patients who have not responded to other treatments.
Duodenal mucosal resurfacing (known as ‘DMR’) is a procedure that selectively ablates the duodenal mucosa through hydrothermal ablation... showed a clinically significant reduction in HbA1c following a single procedure... when stratifying for high fasting glucose (>10 mmol/L), HbA1c reduction with DMR was significant (–14.2 vs. −4.4; p = 0.002)
Why this rating
Based on open-label studies and early RCTs; one RCT missed primary outcome but showed subgroup significance; safety data is emerging.
Source
Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?
Benjamin Norton et al. · Gastrointestinal Disorders · 2024
DOI 10.3390/gidisord6010013
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →